NCT02658448View on ClinicalTrials.gov

GTx-024 as a Treatment for Stress Urinary Incontinence in Women

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Stress Urinary Incontinence
Interventions
DRUG

GTx-024

GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg

Trial Locations (3)

19004

Urologic Consultants of Southeastern Pennsylvania, Bala-Cynwyd

19104

Penn Center for Continence and Pelvic Health, University of Pennsylvania, Philadelphia

48073

William Beaumont Hospital, Royal Oak

Sponsors

Lead Sponsor

GTx
All Listed Sponsors
lead

GTx

INDUSTRY

NCT02658448 - GTx-024 as a Treatment for Stress Urinary Incontinence in Women | Biotech Hunter | Biotech Hunter